Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections.
Vivax malaria accounts for 80% of malaria cases in Mumbai (Bombay) and has high morbidity. In India, the standard treatment to prevent relapses of vivax malaria is a 5-day regimen of primaquine. However, between 1977 and 1997, the efficacy of this treatment declined from approximately 99% to 87%. The efficacy of the 5-day regimen was therefore compared with that of the 14-day regimen currently recommended by the World Health Organization, in Mumbai. The relapse rates observed, over a 6-month period of follow-up, were 0% with the 14-day regimen, 26.7% with the 5-day, and 11.7% when no primaquine treatment was given. The expenditure incurred on the door-to-door dispensing of the 5-day regimen appears to be without benefit. There is an urgent need to review the present strategy for controlling relapses in vivax malaria, at least for the city of Mumbai, and similar studies need to be carried out in other parts of India, to make all anti-relapse strategies more appropriate.
Gogtay
N J
NJ
Department of Clinical Pharmacology, Seth G. S. Medical College, Parel, Mumbai, India.
Desai
S
S
Kamtekar
K D
KD
Kadam
V S
VS
Dalvi
S S
SS
Kshirsagar
N A
NA
D000962:Antimalarials / Q000008:administration & dosage*; D002738:Chloroquine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D007194:India; D016780:Malaria, Vivax / Q000188:drug therapy* / Q000517:prevention & control; D011319:Primaquine / Q000008:administration & dosage*; D055502:Secondary Prevention; D016896:Treatment Outcome
D000962:Antimalarials; D002738:Chloroquine; D011319:Primaquine